



## **ASX ANNOUNCEMENT**

### **Lumos Diagnostics Partners with PRO-spectus to Accelerate Market Access and Reimbursement for FebriDx®**

**MELBOURNE, Australia (14 August 2025)** – Lumos Diagnostics Holdings Ltd (ASX:LDX, “Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies is pleased to announce that it has entered into a partnering agreement with US-based market access consultancy, PRO-spectus, to support the marketing, market access, and reimbursement of its flagship point-of-care test, FebriDx®. The program will initially run through to December 2026.

With reimbursement for FebriDx® now available through US Medicare, Lumos will focus on securing coverage from US private insurance payors to further broaden patient access. Private payors account for approximately 60% of the US health insurance market, covering more than 170 million Americans, with a small number of large insurers controlling nearly half the market. At the same time, the private payor market also includes hundreds of smaller insurers, which, while collectively important, are more difficult to reach and require a targeted approach. By addressing both the large and smaller players, Lumos aims to ensure more healthcare providers and patients can benefit from access to FebriDx®.

Under the agreement, PRO-spectus will provide a comprehensive suite of strategic and operational services designed to help accelerate patient access to FebriDx® by supporting healthcare providers in securing appropriate reimbursement. The partnership will deliver:

- **Market Access Consulting Services** – Development of strategic collateral to communicate FebriDx’s® clinical and economic value across multiple healthcare settings.
- **Reimbursement Helpline Team** – A dedicated helpline to respond to coding, coverage, and payment inquiries from both internal stakeholders and external customers.
- **Access & Reimbursement Manager Services** – A field support team with expertise in provider adoption of new technologies, working directly with strategic accounts to deliver reimbursement education, navigate payor requirements, and resolve site-specific billing and coding challenges.

These services will be integrated with Lumos’ field sales efforts to ensure healthcare providers receive the necessary tools, education, and hands-on support to adopt FebriDx® and to secure reliable reimbursement from insurers for its use.

Lumos CEO, Doug Ward, said: *“This partnership with PRO-spectus is an important step in accelerating the commercial adoption of FebriDx® in the US market. By combining our clinically proven diagnostic technology with PRO-spectus’ market access expertise, we can better equip healthcare providers to secure reimbursement and accelerate the adoption of FebriDx®. Ultimately, this means reducing unnecessary antibiotic use, improving patient outcomes, and helping to address the growing challenge of antimicrobial resistance.”*

PRO-spectus is a leading independent provider of patient access programs and specialty pharmacy services for the life sciences industry. With over 18 years of experience supporting innovative start-ups across 20+ therapeutic classes, the company blends tech-enabled solutions with high-touch, patient-first support to remove traditional market barriers and accelerate patient access to therapy. Its integrated solutions span the entire patent journey for therapies that can benefit from additional licensed clinical expertise, technical reimbursement acumen, and innovative payor management insight to deliver measurable improvements in therapy access and adherence.

Danica Carlson, Chief Operating Officer of PRO-spectus, said: *“We’re thrilled to partner with Lumos Diagnostics to support the expansion of FebriDx® in the US market. Our team is dedicated to helping patients receive access to rapid, accurate diagnosis of their symptoms, supporting provider care decisions that avoid unnecessary antibiotic use and promote better long-term health. FebriDx® represents a meaningful advancement in respiratory infection management, and we’re proud to help bring it to more communities.”*

**-Ends-**

***This announcement has been approved by the Lumos Disclosure Committee.***

#### **About FebriDx®**

FebriDx® is a rapid, point-of-care test that helps healthcare professionals differentiate between bacterial and non-bacterial respiratory infections in around 10 minutes, supporting more informed clinical decision-making and potentially reducing unnecessary antibiotic prescribing.

#### **About Lumos Diagnostics,**

*Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.*

*For more information visit [lumosdiagnostics.com](https://lumosdiagnostics.com).*

**Forward-Looking Statements**

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*

**Media Contacts:**

Haley Chartres – Australia

HACK Director

[haley@hck.digital](mailto:haley@hck.digital)

+61 423 139 163

**Investor Contact:**

George Kopsiaftis

IR Specialist, IR Department

[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)

+61 409 392 687

**Company Registered Office:**

Lumos Diagnostics Holdings Ltd

Suite 2, Level 11, 385 Bourke Street

Melbourne, VIC 3000

[info@lumosdiagnostics.com](mailto:info@lumosdiagnostics.com)

+61 3 9087 1598